Literature DB >> 3769206

Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone.

E Farish, C D Fletcher, D M Hart, M M Dagen, D E Parkin.   

Abstract

Lipoprotein and apolipoprotein levels were monitored in 21 postmenopausal women during 6 months' treatment with norethisterone. There was no significant change in low density lipoprotein (LDL) cholesterol but apoprotein B levels rose significantly (p less than 0.001) thus increasing the apoprotein:cholesterol ratio in LDL. High density lipoprotein (HDL) cholesterol levels decreased significantly (p less than 0.001) in the first two months and did not change significantly thereafter. The HDL2 subfraction was reduced to a greater extent than the HDL3 subfraction. Apoprotein AI and AII levels were both reduced as was the apoprotein AI:AII ratio. The ratios of apoproteins AI and AII to HDL cholesterol were increased. We conclude that norethisterone has an adverse effect on the important risk factors for cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3769206     DOI: 10.1016/0009-8981(86)90047-1

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Lipoprotein (a) concentrations in postmenopausal women taking norethisterone.

Authors:  E Farish; H A Rolton; J F Barnes; D M Hart
Journal:  BMJ       Date:  1991-09-21

Review 2.  Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.